Oncology Drug DiscoveryRecent Publications:1. Sung M., Tan X., Lu B., Golas J., Hosselet C., Wang F., Tylaska L., King L., Zhou D., Dushin R., Myers J.S., Rosfjord E., Lucas J., Gerber HP, and Loganzo F. (2018) Caveolae-mediated endocytosis as a novel mechanism of resistance to trastuzumab emtansine (T-DM1). Mol Cancer Ther. 17(1) 243-53.2. Damelin, M., Bankovich, A., Bernstein, J., Lucas, J., Chen, L., Williams, S., Park, A., Aguilar, J., Ernstoff, E., Charati, M., Dushin R., Aujay M., Lee C., Ramoth H., Milton M., Hampl J., Lazetic S., Pulito V., Rosfjord E., Sun Y., King L., Barletta F., Betts A., Guffroy M., Falahatpisheh H., O'Donnell C.J., Stull R., Pysz M., Escarpe P., Liu D, Foord O, Gerber HP., Sapra P, and Dylla S.J. (2017) A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions. Sci Transl Med. 9(372).3. Shor B, Kahler J, Dougher M, Xu J, Mack M, Rosfjord E, Wang F, Melamud E, and Sapra P (2015) Enhanced Anti-Tumor Activity Of an anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes. Clin Cancer Res. 4. Rosfjord, E, Lucas, J, Li, G, and Gerber, HP (2014) Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology. Biochem Pharmacol. 91(2):135-43.5. Dann SG, Golas J, Miranda M, Shi C, Wu J, Jin G, Rosfjord E, Upeslacis E, and Klippel A (2014) p120 catenin is a key effector of a Ras-PKCɛ oncogenic signaling axis. Oncogene 33(11) 1385-1394.6. Unsal-Kacmaz, K, Ragunathan, S, Rosfjord, E, Dann, S, Upeslacis, E, Grillo, M, Hernandez, R, Mack, F, and Klippel, A (2012) The interaction of PKN3 with RhoC promotes malignant growth. Molecular Oncology 6(3) 284-298.Patent Applications:1. United States Patent Application 20090270447: 2. United States Patent Application 20090270363:3. World Patent Application: WO/2009/120849: 4. World Patent Application: WO/2009/120826:

Publications:1. M. Grillo, MJ Bott, N Khandke, JP McGinnis, M Miranda, M Meyyappan, EC Rosfjord, SK Rabindran. (2006) Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression. Breast Cancer Research and Treatment 95(2):185-1942. SK Rabindran, CM Discafani, EC Rosfjord, M Baxter, MB Floyd, J Golas, WA Hallett, BD Johnson, R Nilakantan, E Overbeek, MF Reich, R Shen, X Shi, HR Tsou, YF Wang, A Wissner (2004) Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Research. 64:3958-3965.3. A Wissner, E Overbeek, MF Reich, MB Floyd, BD Johnson, N Mamuya, EC Rosfjord, C Discafani, R Davis, X Shi, SK Rabindran, BC Gruber, F Ye, WA Hallett, R Nilakantan, R Shen, YF Wang, LM Greenberger, HR Tsou. (2003) Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J Med Chem. 46:49-63.

Postdoctoral Fellow in Robert Dickson's Laboratory. Lombardi Cancer Center.

PhD graduate student in the laboratory of Dr. Angie Rizzino in the Eppley Cancer Center.

Assistant Patent Examiner reviewing patent applications describing organic compounds and their method of use.Listed as Assistant Examiner on 6 U.S. Patents published between May and August 1990: 1. 4,948,582 Treatment of conditions requiring enhanced oxygen availability to mammalian tissues 2. 4,942,041 Pharmaceutical compositions effective for treating skin to destroy eggs of enterobius vermicularis 3. 4,940,575 4-hydroxyisoxazole derivatives, method of preparing same, and cosmetic and pharmaceutical compositions containing them 4. 4,939,268 4-(meth)acrylamidomethyl)-pyrazoles and -isoxazoles, their preparation and their use 5. 4,925,955 Resolution of (1S,4R)-1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl) pyrano[3,4-B]indole-1-acetic acid using brucine 6. 4,923,996 Optically active rhodium complexes of 3,4-bis(diarylphosphino)pyrrolidines and their use for the preparation of phosphinothricin by asymmetric hydrogenation